These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 24659578

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate.
    Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhäuser J, Rogers PD.
    Eukaryot Cell; 2008 Jul; 7(7):1180-90. PubMed ID: 18487346
    [Abstract] [Full Text] [Related]

  • 4. UPC2A is required for high-level azole antifungal resistance in Candida glabrata.
    Whaley SG, Caudle KE, Vermitsky JP, Chadwick SG, Toner G, Barker KS, Gygax SE, Rogers PD.
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4543-54. PubMed ID: 24867980
    [Abstract] [Full Text] [Related]

  • 5. Upc2-mediated mechanisms of azole resistance in Candida auris.
    Li J, Aubry L, Brandalise D, Coste AT, Sanglard D, Lamoth F.
    Microbiol Spectr; 2024 Feb 06; 12(2):e0352623. PubMed ID: 38206035
    [Abstract] [Full Text] [Related]

  • 6. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans.
    Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhäuser J, Rogers PD.
    Eukaryot Cell; 2012 Oct 06; 11(10):1289-99. PubMed ID: 22923048
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and CDR1 Expression in Candida albicans.
    Nishimoto AT, Zhang Q, Hazlett B, Morschhäuser J, Rogers PD.
    Antimicrob Agents Chemother; 2019 May 06; 63(5):. PubMed ID: 30833425
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans.
    Sasse C, Schillig R, Dierolf F, Weyler M, Schneider S, Mogavero S, Rogers PD, Morschhäuser J.
    PLoS One; 2011 May 06; 6(9):e25623. PubMed ID: 21980509
    [Abstract] [Full Text] [Related]

  • 12. Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans.
    Morio F, Pagniez F, Besse M, Gay-andrieu F, Miegeville M, Le Pape P.
    Int J Antimicrob Agents; 2013 Nov 06; 42(5):410-5. PubMed ID: 24051054
    [Abstract] [Full Text] [Related]

  • 13. Impact of ERG3 mutations and expression of ergosterol genes controlled by UPC2 and NDT80 in Candida parapsilosis azole resistance.
    Branco J, Ola M, Silva RM, Fonseca E, Gomes NC, Martins-Cruz C, Silva AP, Silva-Dias A, Pina-Vaz C, Erraught C, Brennan L, Rodrigues AG, Butler G, Miranda IM.
    Clin Microbiol Infect; 2017 Aug 06; 23(8):575.e1-575.e8. PubMed ID: 28196695
    [Abstract] [Full Text] [Related]

  • 14. Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence.
    Lohberger A, Coste AT, Sanglard D.
    Eukaryot Cell; 2014 Jan 06; 13(1):127-42. PubMed ID: 24243794
    [Abstract] [Full Text] [Related]

  • 15. The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans.
    Sasse C, Dunkel N, Schäfer T, Schneider S, Dierolf F, Ohlsen K, Morschhäuser J.
    Mol Microbiol; 2012 Nov 06; 86(3):539-56. PubMed ID: 22924823
    [Abstract] [Full Text] [Related]

  • 16. Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans.
    Barker KS, Crisp S, Wiederhold N, Lewis RE, Bareither B, Eckstein J, Barbuch R, Bard M, Rogers PD.
    J Antimicrob Chemother; 2004 Aug 06; 54(2):376-85. PubMed ID: 15201233
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. UPC2 mutations and development of azole resistance in Candida albicans hospital isolates from Lebanon.
    Fattouh N, Hdayed D, Hijazi A, Tokajian S, Khalaf RA.
    J Glob Antimicrob Resist; 2024 Sep 06; 38():341-348. PubMed ID: 39059553
    [Abstract] [Full Text] [Related]

  • 19. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D, Coste AT.
    Antimicrob Agents Chemother; 2016 Jan 06; 60(1):229-38. PubMed ID: 26482310
    [Abstract] [Full Text] [Related]

  • 20. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans.
    Hoot SJ, Smith AR, Brown RP, White TC.
    Antimicrob Agents Chemother; 2011 Feb 06; 55(2):940-2. PubMed ID: 21078937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.